Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Top Cited Papers
Open Access
- 8 February 2017
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 49
- https://doi.org/10.3389/fphar.2017.00049
Abstract
The indications of immune checkpoint inhibitors (ICIs) is set to rise further with the approval of newer agents like tremelimumab and atezolimumab for use in patients with advanced stage mesothelioma and urothelial carcinoma respectively. More frequent use of ICIs has improved our understanding of their unique side effects, which are known as immune-related adverse events (irAEs). The spectrum of irAEs has expanded beyond more common manifestations such as dermatological, gastrointestinal and endocrine effects to rarer presentations involving nervous, hematopoietic and urinary systems. There are new safety data accumulating on ICIs in patients with previously diagnosed autoimmune conditions. It is challenging for clinicians to continuously update their working knowledge to diagnose and manage these events successfully. If diagnosed timely, the majority of events are completely reversible, and temporary immunosuppression with glucocorticoids, infliximab or other agents is warranted only in the most severe grade illnesses. The same principles of management will possibly apply as newer anti- cytotoxic T lymphocytes-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1/PD-L1) antibodies are introduced. The current focus of research is for prophylaxis and for biomarkers to predict the onset of these toxicities. In this review we summarize the irAEs of ICIs and emphasize their growing spectrum and their management algorithms, to update oncology practitioners.Keywords
This publication has 81 references indexed in Scilit:
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse eventsJournal of Translational Medicine, 2013
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced MelanomaJournal of Clinical Oncology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV MelanomaJournal of Clinical Oncology, 2012
- Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patientAnnals of Oncology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV MelanomaClinical Cancer Research, 2009
- Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related ColitisCancer Biotherapy & Radiopharmaceuticals, 2009
- Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)Journal of Immunotherapy, 2009
- Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4Journal of Clinical Oncology, 2005